Discounted Cash Flow (DCF) Analysis Unlevered

NeuroSense Therapeutics Ltd. (NRSN)

$1.8

+0.16 (+9.76%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.8 | undervalue

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
Revenue (%)
EBITDA -------
EBITDA (%)
EBIT -------
EBIT (%)
Depreciation -------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash -------
Total Cash (%)
Account Receivables -------
Account Receivables (%)
Inventories -------
Inventories (%)
Accounts Payable -------
Accounts Payable (%)
Capital Expenditure -------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.8
Beta 0.000
Diluted Shares Outstanding 10.94
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.705
Total Debt -
Total Equity 19.70
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
EBITDA -------
EBIT -------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -------
Depreciation -------
Accounts Receivable -------
Inventories -------
Accounts Payable -------
Capital Expenditure -0.01-0.01-----
UFCF -------
WACC
PV UFCF -------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -0.70
Equity Value -
Shares Outstanding 10.94
Equity Value Per Share -